Rep. Jodey Arrington (R-TX) said Wednesday (Nov. 17) the government should vary drug exclusivity periods based on the value of drugs to society, and Rep. Scott Peters (D-CA) said he’d like to work with Arrington on that idea. However, it’s unclear whether there will be much appetite for taking on additional drug pricing reforms now that House Democrats have passed the scaled-back Medicare price negotiation deal largely brokered by Peters as part of their Build Back Better legislation….read more here >>
“I don’t believe we should have a one-size-fits-all exclusivity path, which is a monopoly, for all products and all-size markets and all profit margins,” Arrington said during an event organized by the Council for Affordable Health Coverage. “There should be nuance to that.”